A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
Study sponsor: Relmada Therapeutics, Inc. · RLMD
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-11-01Actual
Enrollment · participants227Actual
Source updated2024-08-27Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.